Patents by Inventor Christiane Regina Stadler

Christiane Regina Stadler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
    Publication number: 20200390887
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.
    Type: Application
    Filed: August 31, 2020
    Publication date: December 17, 2020
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Denis Jacobs, Magdalena Jadwiga Utsch, Cornelia Adriana Maria Heinz, Christiane Regina Stadler
  • Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer
    Patent number: 10813996
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: October 27, 2020
    Assignees: ASTELLAS PHARMA INC., TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT AT MAINZ GEMEINNUTZIGE GMBH
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Denis Jacobs, Magdalena Jadwiga Utsch, Cornelia Adriana Maria Heinz, Christiane Regina Stadler
  • COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
    Publication number: 20180326059
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.
    Type: Application
    Filed: May 7, 2018
    Publication date: November 15, 2018
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Denis Jacobs, Magdalena Jadwiga Utsch, Cornelia Adriana Maria Heinz, Christiane Regina Stadler
  • COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
    Publication number: 20180258180
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.
    Type: Application
    Filed: March 1, 2018
    Publication date: September 13, 2018
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Denis Jacobs, Magdalena Jadwiga Utsch, Cornelia Adriana Maria Heinz, Christiane Regina Stadler
  • Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer
    Patent number: 10022444
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: July 17, 2018
    Assignees: GANYMED PHARMACEUTICALS AG, TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Denis Jacobs, Magdalena Jadwiga Utsch, Cornelia Adriana Maria Heinz, Christiane Regina Stadler
  • COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
    Publication number: 20160339101
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.
    Type: Application
    Filed: August 8, 2016
    Publication date: November 24, 2016
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Denis Jacobs, Magdalena Jadwiga Utsch, Cornelia Adriana Maria Heinz, Christiane Regina Stadler
  • Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
    Patent number: 9433675
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: September 6, 2016
    Assignees: Ganymed Pharmaceuticals AG, TRON—Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz Gemeinnutzige GmbH
    Inventors: Ugur Sahin, Özlem Türeci, Rita Mitnacht-Kraus, Stefan Denis Jacobs, Magdalena Jadwiga Utsch, Cornelia Adriana Maria Heinz, Christiane Regina Stadler
  • COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
    Publication number: 20150157711
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.
    Type: Application
    Filed: May 21, 2013
    Publication date: June 11, 2015
    Applicants: Ganymed Pharmaceuticals AG, TRONTRANSLATIONALE ONKOLOGIE AN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH
    Inventors: Ugur Sahin, Özlem Türeci, Rita Mitnacht-Kraus, Stefan Denis Jacobs, Magdalena Jadwiga Utsch, Cornelia Adriana Maria Heinz, Christiane Regina Stadler
  • COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
    Publication number: 20150132253
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.
    Type: Application
    Filed: May 21, 2013
    Publication date: May 14, 2015
    Applicants: GANYMED PHARMACEUTICALS AG, TRON - Translationale Onkologie an der Johannes Gutenberg-Universitat Mainz gemeinnuetzige GmbH
    Inventors: Ugur Sahin, Özlem Türeci, Rita Mitnacht-Kraus, Stefan Denis Jacobs, Magdalena Jadwiga Utsch, Cornelia Adriana Maria Heinz, Christiane Regina Stadler